---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-26-000077"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2026-08-21T12:01:10+00:00"
generated_at: "2026-08-21T12:05:07.548084+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio raises $25M initial private placement, up to $225M more tied to FDA milestones

## Summary
- Initial closing expected Aug 24, 2026: ~$25M gross from pre-funded warrants at $0.1399/share.
- Second closing of ~$125M upon FDA acceptance of NDA for seralutinib in PAH; FDA Approval Warrants add ~$100M.
- Proceeds to fund clinical development and commercialization of seralutinib in PAH and PH-ILD.
- Warrants exercisable for preferred stock pre-stockholder approval, then common stock; conversion prices $0.14 and $0.187.
- Company lock-up until FDA approval warrants exercised or Dec 31, 2026 if second closing not met.

## SEC filing metadata
- accession: 0001728117-26-000077
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2026-08-21T12:01:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/0001728117-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/goss-20260820.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-26-000077
- JSON: https://secwatch.observer/filing/0001728117-26-000077.json
- Plain text: https://secwatch.observer/filing/0001728117-26-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.